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Abstract
Cryptococcus neoformans is the most common cause of
life  threatening  meningoencephalitis  in  HIv-infected
patients. Diagnosis is based on tests for cryptoccocal
antigen in serum and cerebrospinal fluid, and on cul-
ture of the organism. We present a case of AIDs-relat-
ed  cryptococcal  meningoencephalitis  unresponsive  to
antifungal combination therapy, despite of evidence of
fungal  susceptibility  in  vitro.  significant  decreases  in
cryptococcal antigen titers in serum and cerebrospinal
fluid did not correlate with progress in disease and fatal
outcome. 
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IntRoDuCtIon
Cryptococcosis  is  a  life-threatening  fungal  infection,
caused by Cryptococcus (C.) neoformans, an encapsu-
lated yeast. Primary infection develops in the lungs by
inhalation and remains asymptomatic in the majority of
immunocompetent hosts [1]. t cell-related immunode-
ficiency, most commonly in association with HIv infec-
tion is a major predisposing factor for cerebral crypto-
coccosis.  Disseminating  disease  may  develop  as  an
AIDs  defining  disease  in  HIv  infected  individuals  –
predominantly in patients with CD4+ t cell count less
than 100/ﾵl [2] - and presents in up to 80% as meningi-
tis or meningoencephalitis [3]. Positive direct staining
or culture of cerebrospinal fluid (CsF) and/or antigen
testing  in  CsF  ensures  the  diagnosis  of  cryptococcal
meningitis (CM) [4] and a positive serum cryptococcal
antigen (CrA) titer is suggestive for dissemination [5].
In HIv infected individuals responding to active anti
retroviral therapy (HAARt) and prior cryptococcal in-
fection, cases of immune reconstitution inflammatory
syndrome (IRIs) related CM have been described [6].
In a recent prospective study the incidence of CM-IRIs
was found to be 17% [7]. Poor prognosis has been as-
sociated with a number of risk factors in AIDs-related
CM. A serum CrA-titer ≥ 1:512 [8], a CsF CrA-titer ≥
1:1024 [9], culture of  Cryptococcus from CsF >106
CFu/ml, a CsF leukocyte count ≤20 cells/ﾵl, and ini-
tial alteration in mental status [8, 10-12]. treatment of
CM requires induction therapy with a combination of
at least two drugs. success of antifungal induction ther-
apy should be monitored by culturing CsF for Cryto-
coccus. After 2 weeks of therapy with amphotericin b
plus  flucytosine,  CsF  culture  results  are  negative  in
60% to 75% [13, 14].
CAsE REPoRt
HIv infection was diagnosed in May 2008, in a 33 year
old homosexual man who presented to another hospital
with fever and unproductive cough. Chest X-ray and
Ct-scans revealed diffuse homogeneous ground glass
opacity in both lungs and pneumocystis jiroveci could
be  de  monstrated  in  bronchoalveolar  lavage  (bAl).
standard  therapy  with  trimethoprim-sulfamethoxazole
(tMP-sMZ) and prednisolone was successful. Replica-
tive  HIv  infection  could  be  proven  by  PCR  (91.000
copies/ml) and the CD4 cell-count of 59/ﾵl indicated a
profound immunodeficiency. thus HAARt was started
with  tenofovir/emtricitabine  and  lopinavir/ritonavir.
two months later the patient was admitted to our clinic
with  increasing  headache,  emesis,  lethargy  and  focal
seizures for the past 4 weeks. Cerebral symptoms began
with mild headaches 3 weeks prior to admission. Initial-
ly  performed  magnet  resonance  imaging  (MRI)  scan
showed bihemispheric mass right more than left in basal
ganglia area, which was not present on a MRI done 3
weeks before admission. Ring enhancement of these le-
sions was absent. At this point there were no signs of
elevated intracranial pressure (ICP) on MRI (Fig. 1).
A lumbar punction performed on the same day re-
vealed  a  CsF  leukocyte  count  of  10/ﾵl,  positive  CsF
CrA (1:8192) with positive India ink test. Encapsulated
C. neoformans var grubii isolates growing on culturewere
sensitive to amphotericin b, fluconazole and flucytosine.
serum CrA-titer was elevated with 1:32.768. Culture
of CsF for bacteria, including mycobacteria remained
negative, so did specific test for Treponema  pallidum,
Toxoplasma gondii and JC-virus. on admission the viral
load was undetectable and the CD4 cell-count was still
low (44/ﾵl). 
An  intravenous  antifungal  drug  combination  with
fluconazole 400mg/d, flucytosine (150mg/kg/d) and li-
posomal amphotericin b (4mg/kg/d) was administered.
Due to a rapid virological response under HAARt, ini-
tially  an  IRIs-associated  CM  could  not  be  excluded.
therefore dexamethasone was given additionally to an-
tifungal combination therapy.
Initially the patient improved mildly in mental status
and serum CrA-titer dropped by 3 titer steps to 1:4096
one week after initiating antifungal therapy. 
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unexpectedly  clinically  worsened  continually  with  in-
crease in seizure frequency. Another lumbar puncture
performed  revealed  a  3  titer  steps  decrease  of  CsF
CrA-titer  (1:1024).  yet  the  cryptococci  were  still  cu-
tured from CsF. At this point a stereotactic brain biop-
sy  from  suspected  area  was  done.  biopsy  (Fig.  2)
showed  accumulation  of  C.  neoformans within  brain
parenchyma  with  little  cellular  immune  reaction  and
without any evidence of granulomatous encephalitis.
During biopsy, an increased opening pressure of 462
mm of water (physiological pressure < 200 mm of wa-
ter)  could  be  measured.  brain  Ct-scan  obtained
showed brain edema but no hydrocephalus, a common
cause for elevated intracerebral pressure in CM (Fig. 1).
Due to the risk of herniation, reduction of ICP at that
time point would have require trepanation, which was
denied by health care directives from the patient and
his relatives. 
DIsCussIon
HIv-associated CM is an AIDs defining disease, indi-
cating an advanced immunodeficiency. 
Without therapy death by CM usually occurs within
2-4 weeks of diagnosis [12]. In a nationwide surveil-
lance in France a significant decrease of average mor-
tality  rate  in  the  HAARt  era  (15.3  per  100  person-
years) compared to the pre-HAARt era (63.8 per 100
person-years) could be shown in AIDs defining crypto-
coccosis. Despite that decrease early mortality remained
high [15]. In the literature CM associated mortality in
patients under antifungal therapy is determined to be
over 20% in the first 3 months after diagnosis [15, 16]. 
In  accordance  with  the  described  risk  factors  the
presented  case  fulfils  criteria  for  severe  cryptococcal
cerebral infection. He initially presented with mental al-
teration, had a high serum CrA-titer of 1:32.768 and a
CsF CrA-titer of 1:8.192, a low CsF leukocyte count of
10/ﾵl and positive culture for C. neoformans.
A rapid establishment of antifungal activity within
affected tissue should be the primary goal of any in-
duction therapy. In germany a triple therapy with am-
photericin  b,  flucytosine  and  fluconazole  is  recom-
mended for meningitis. the rate for complete remis-
sion of meningitis, which is achieved in around 80 % of
patients  [17],  may  be  slightly  higher  than  under  dual
therapy with amphotericin b and flucytosine as favored
in the united states [14].
Elevated ICP in the presented case was due to brain
edema without any signs of hydrocephalus on imaging.
According to the guidelines of IDsA managing of ICP
by lumbar punctures or external drainage is indicated in
ICP caused by hydrocephalus [18]. Due to the risk of
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fig.  1.  series of cere-
bral  images  in  the
course of infection. A)
cerebral  MRI  3  weeks
prior  to  admission;  b)
MRI  on  admission
with  bihemispheric
mass  right  more  than
left  in  basal  ganglia
area  (arrow);  C)  Cere-
bral  Ct  after  3  weeks
of antifungal combina-
tion  therapy  with  loss
of  gray-white  distinc-
tion and effacement of
cerebral sulci.
fig. 2. brain tissue infection with encapsulated C. neoformans
appears as bubbles due to gelatinous capsules. Reproducing by
budding (arrow) PAs-stain, magnification, x400. 
fig.  3.  Course  of  serum  cryptococal  antigen  titer,  antifungal
antigen  titer,  antifungal  combination  therapy,  ICP  controlling
therapy and the course of disease. 
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not  allow  lumbar  puncture.  trepanation  as  the  treat-
ment of choice was denied by relatives. As an option of
conservative  ICP  controlling  therapy  mannitol  and
sedatives were administered. However prognosis in cas-
es with elevated ICP remains poor also in cases with in-
ternal hydrocephalus. Although invasive measures can
reduce ICP, a survival benefit over 2 or 10 weeks was
absent in a prospective study [16]. 
Clinical  progress  occurred  despite  an  appropriate
combination therapy with fluconazole, flucytosine and
liposomal amphotericin b and evidence of fungal sus-
ceptibility – guidelines defined by ClsI 2008 [23] – in
the initial as in the follow up CsF culture and indicates
the  limited  clinical  correlation  of  resistance  tests  and
clinical efficacy in CM.  Progress of infection is suggest-
ed by a positive CsF culture after two weeks as well by
histological demonstration of C. neoformans with signs
of reproducing by budding but a lack of significant in-
flammatory signs. Predominance of IRIs-related CM is
unlikely in this case due to: (i) persistent positive culture
from  CsF;  (ii)  histological  demonstration  of  vital  C.
neoformans with signs of fungal growth; (iii) absence of
granulomatous inflammation, which would be the ex-
pected type of inflammation in HIv-negative patients
[19] and in IRIs-related cryptoccocal infections [6].
In contrast to the clinical progression of the infec-
tion  serological  and  CsF-titers  for  Cryptococcus de-
creased under therapy. Although sequential monitoring
of elevated CrA in serum and CsF suggests to reflect
directly the burden of fungal pathogen, it is potentially
misleading and therefore not recommended as a surro-
gate marker to follow-up AIDs-related cryptococcal in-
fection during therapy [12, 20-22].
In conclusion careful and close clinical observation,
neuroimaging and direct confirmation of CsF sterility
by lumbar puncture or biopsy are crucial in the moni-
toring during the acute phase of cryptococcal disease.
As shown in the presented case a decrease of CrA in
serum and CsF is not a reliable parameter for the re-
sponse to antifungal treatment in the presented case.
the primary failure of treatment occurred despite ini-
tial use of three recommended elements of an antifun-
gal  combination  therapy,  and  in  the  absence  of  evi-
dence  for  primary  resistance  in  vitro  of  the  isolated
cryptococci. 
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